Sleep Apnea, Obstructive
Conditions
Brief summary
Obstructive sleep apnea (OSA) is a highly prevalent disease resulting from dynamic upper airway collapse during sleep. Continuous positive airway pressure (CPAP) is highly efficacious but high rates of non-adherence to CPAP leaves large number of OSA patients at risk for cardiometabolic sequelae. Inspire™ is an FDA-approved hypoglossal nerve stimulation device (HGNS) used in select patients with OSA who are intolerant of CPAP. The device consists of an implanted impulse generator with a stimulating cuff lead around the distal hypoglossal nerve. Despite these stringent selection criteria, up to one-third of patients implanted have inadequate responses to HGNS and remain at risk for complications from untreated OSA. The current proposal builds on routine clinical care to characterize upper airway biomechanics and determine predictors of clinical responses to HGNS therapy. Drug induced sleep endoscopy (DISE) is a prerequisite for HGNS treatment and represents an ideal opportunity to rapidly characterize upper airway dynamics under controlled, standardized conditions. The amount of nasal pressure required to relieve airway obstruction (minimal therapeutic pressure) is a significant predictor of successful treatment of OSA with HGNS. As a result, CPAP titration (measuring pharyngeal collapse patterns at varying nasal pressures) has become an integral part of DISE to select parties for HGNS at multiple institutions. Nevertheless, changes in upper airway collapsibility in response HGNS may differ significantly between patients. This stud will examine if changes in upper airway patency with direct genioglossus muscle stimulation at the time of DISE predicts successful treatment with HGNS as defined by a 50% reduction on apnea-hypopnea index (AHI) and an on-treatment AHI \<20.
Interventions
None listed
Sponsors
American Academy of Sleep Medicine
Johns Hopkins University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Male and female participants with moderate or severe sleep apnea (defined by \> 15 apneas and hypopneas per hour of sleep), who are undergoing DISE as part of routine evaluation for Inspire hypoglossal nerve stimulation therapy or for ineffective HGNS therapy.
Exclusion criteria
* Significant cardiac disease, unstable or recent cardiac events * Active pulmonary, liver or renal disease * Uncontrolled hypertension (BP\>160/100) * Neuromuscular disease * Major psychiatric disease * Pregnancy * Anticoagulation therapy (e.g. Coumadin, Dabigatran)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tidal airflow with direct genioglossus stimulation | at the time of drug-induced sleep endoscopy, up to 1 hour | Tidal airflow (mL) with direct stimulation of the genioglossus muscle will be measured at the time of drug-induced sleep endoscopy. |
| HGNS therapy success as assessed by the apnea hypopnea index | at 1 year post HGNS implantation | Successful treatment with HGNS, as defined by a 50% reduction in apnea hypopnea index (AHI) and an on-therapy AHI of \<15 (the same criteria as in major trials of non-CPAP OSA treatment). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Therapeutic CPAP pressure with direct genioglossus stimulation | At the time of drug-induced sleep endoscopy, up to 1 hour | Therapeutic CPAP pressure (cmH20) with direct stimulation of the genioglossus muscle will be measured at the time of drug-induced sleep endoscopy. |
| Airway critical closing pressure with direct genioglossus stimulation | At the time of drug-induced sleep endoscopy, up to 1 hour | Airway critical closing pressure (cmH20) with direct stimulation of the genioglossus muscle will be measured at the time of drug-induced sleep endoscopy. |
Countries
United States
Contacts
Primary ContactKevin M Motz
Outcome results
None listed